Loading
FGF2 (Fibroblast growth factor 2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Acute myeloid leukaemia.
Acts as a ligand for FGFR1, FGFR2, FGFR3 and FGFR4. Also acts as an integrin ligand which is required for FGF2 signalling. Binds to integrin ITGAV:ITGB3.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Quizartinib. Open Targets scores its association with cancer at 0.71 (direct and indirect evidence; datatypes clinical 0.62, affected pathway 0.99, literature 0.99, genetic association 0.00, animal model 0.55).
In plain words · FGF2 (Fibroblast growth factor 2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Acute myeloid leukaemia.
FGF2 (Fibroblast growth factor 2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Acute myeloid leukaemia.
Acts as a ligand for FGFR1, FGFR2, FGFR3 and FGFR4. Also acts as an integrin ligand which is required for FGF2 signalling.
No product in this corpus aims at FGF2 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Broadly expressed or essential: HPA finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA FGF2: RNA low tissue specificity; high antibody staining in 4 normal tissues; highest cancer staining glioma (3 of 12 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Leukaemia); Open Targets associates it with 1 specific cancer type at or above 0.5 (female reproductive endometrioid cancer). (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas FGF2 tissue; Open Targets ENSG00000138685 associations
First described 1986. Earliest sequence paper UniProt cites for the protein: Abraham J.A. et al, Cold Spring Harb. Symp. Quant. Biol, 1986, "Human basic fibroblast growth factor: nucleotide sequence, genomic organization, and expression in mammalian cells". Source.
Sources: HGNC HGNC:3676 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P09038 (protein name, function text, keywords and locations (REST API)); CIViC gene FGF2 (1 evidence items, 0 assertions, 1 variants; diseases: Acute Myeloid Leukaemia (GraphQL API, CC0)); Open Targets ENSG00000138685 (association with cancer (MONDO_0004992) 0.71; (GraphQL API, CC0))
Acts as a ligand for FGFR1, FGFR2, FGFR3 and FGFR4. Also acts as an integrin ligand which is required for FGF2 signalling. Binds to integrin ITGAV:ITGB3. Plays an important role in the regulation of cell survival, cell division, cell differentiation and cell migration. Functions as a potent mitogen in vitro. Can induce angiogenesis. Location: Secreted; Nucleus (UniProt). Locus 4q28.1 (HGNC).
RNA: low tissue specificity, detected in many normal tissues.
Medium: Adipose tissue, Bone marrow, Breast, Cerebral cortex, Colon, Fallopian tube, Hippocampus, Kidney.
Medium only: renal cancer, stomach cancer, thyroid cancer.
HPA FGF2 tissue · HPA FGF2 pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"FGF2" OR ABSTRACT:"FGF2" OR TITLE:"fibroblast growth factor 2" OR ABSTRACT:"fibroblast growth factor 2" OR TITLE:"Fibroblast growth factor 2" OR ABSTRACT:"Fibroblast growth factor 2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FGF2, not a curated reading list.